Researchers work inside a laboratory at BeiGene’s research and development centre in China. Photo: Bloomberg
Researchers work inside a laboratory at BeiGene’s research and development centre in China. Photo: Bloomberg

BeiGene’s Shanghai stock debut flops as excessive premium, running losses keep investors at bay

  • Stock closes 16.4 per cent lower after plunging as much as 19 per cent in intraday trading following its US$3.4 billion onshore stock offering
  • Stock still trades at 22 per cent premium over its Hong Kong-listed securities, versus the market average of 39 per cent in 2021

Topic |   China stock market
Researchers work inside a laboratory at BeiGene’s research and development centre in China. Photo: Bloomberg
Researchers work inside a laboratory at BeiGene’s research and development centre in China. Photo: Bloomberg
READ FULL ARTICLE